Key Highlights

  • U.S. Stem Cell's most recent widely visible corporate update dates to March 2022, when it announced the appointment of Mark Borman as chairman.
  • The company, formerly known as Bioheart, has a regulatory history in which U.S. authorities took legal action over stem-cell procedures, with courts siding with the government.
  • USRM trades near one hundredth of a cent with a market Capitalization in the tens of thousands of dollars in the last closing session.
  • No specific, verifiable catalyst explains current trading, consistent with a company that files and communicates infrequently.

Few names in regenerative medicine carry as complicated a legacy as U.S. Stem Cell, Inc (OTC:USRM). The Florida-based company, once known as Bioheart, spent years promoting autologous cell therapies before regulatory clashes and financial strain pushed it to the margins of the market. Its shares now trade over the counter at a fraction of a cent in the last closing session.

Company and Latest Development

U.S. Stem Cell describes itself as a developer of proprietary, physician-based stem cell and regenerative medicine solutions, historically focused on autologous cellular therapies derived from a patient's own tissue to address conditions such as cardiovascular disease.

The most recent widely visible corporate update on financial-data platforms dates to March 2022, when the company announced the appointment of Mark Borman as chairman of the board. Beyond that, verifiable, market-moving disclosures have been sparse.

What Is Driving Attention Around USRM?

No specific, verifiable catalyst explains current trading. The stock sits at a sub-penny quote with negligible daily movement, the kind of profile that draws occasional speculative attention precisely because the price is so low, not because of concrete news.

USRM's more consequential history lies in its regulatory record: U.S. authorities took legal action over stem-cell procedures marketed by the company and an affiliated clinic, and the courts sided with the government, resulting in injunctive relief.

Key Numbers and Company Position

Reliable current financials are limited. Data providers list the shares around one hundredth of a cent with a market capitalization in the tens of thousands of dollars, figures consistent with a dormant nano-cap but which should be treated as indicative rather than audited.

The company carries no analyst rating. Without recent, verifiable filings detailing revenue, cash or liabilities, investors have little firm numerical footing.

What Could Come Next?

Any genuine catalyst would likely have to come from renewed operational or financing activity: a new clinical or commercial initiative, a capital raise, a reverse merger, or updated financial reporting that re-establishes transparency.

For a company trading at these levels, corporate actions such as reverse splits or share restructurings are also possible, though none is confirmed.

Risks to Watch

The risks are substantial. Sub-penny OTC stocks carry extreme volatility, thin Liquidity and wide spreads, and the lack of current audited financials makes fundamental assessment difficult.

The company's regulatory history underscores the compliance sensitivity of the stem-cell field, where Marketing unapproved therapies invites enforcement. Dilution risk is ever-present for cash-constrained micro-caps.

Regulatory History Overshadows Current Momentum

U.S. Stem Cell, Inc occupies a quiet corner of the regenerative-medicine landscape, its story shaped more by past regulatory battles than by any current pipeline momentum. With USRM trading at a fraction of a cent and public updates scarce since 2022, there is no clearly identifiable catalyst at work.

Investors monitoring the name may want to watch for a return to regular SEC reporting or any concrete operational announcement as the first sign that the company is more than a dormant listing.